OA13017A - Diazepinoindole derivatives as kinase inhibitors. - Google Patents

Diazepinoindole derivatives as kinase inhibitors. Download PDF

Info

Publication number
OA13017A
OA13017A OA1200500197A OA1200500197A OA13017A OA 13017 A OA13017 A OA 13017A OA 1200500197 A OA1200500197 A OA 1200500197A OA 1200500197 A OA1200500197 A OA 1200500197A OA 13017 A OA13017 A OA 13017A
Authority
OA
OAPI
Prior art keywords
phenyl
oxo
dihydro
diazepino
indol
Prior art date
Application number
OA1200500197A
Other languages
English (en)
Inventor
Suzanne BENEDICT
Michael John Bennett
Sacha Ninkovic
Eugene Yuanjin Rui
Min Teng
Yong Wang
Fen Wang
Zhu Jinjiang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of OA13017A publication Critical patent/OA13017A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
OA1200500197A 2003-01-09 2004-01-05 Diazepinoindole derivatives as kinase inhibitors. OA13017A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43939603P 2003-01-09 2003-01-09

Publications (1)

Publication Number Publication Date
OA13017A true OA13017A (en) 2006-11-10

Family

ID=32713475

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200500197A OA13017A (en) 2003-01-09 2004-01-05 Diazepinoindole derivatives as kinase inhibitors.

Country Status (35)

Country Link
US (3) US6967198B2 (xx)
EP (2) EP1947102A1 (xx)
JP (1) JP3990718B2 (xx)
KR (1) KR100697746B1 (xx)
CN (1) CN1759118B (xx)
AP (1) AP2048A (xx)
AT (1) ATE404564T1 (xx)
AU (1) AU2004203977B2 (xx)
BR (1) BRPI0406701A (xx)
CA (1) CA2512683C (xx)
CR (1) CR7899A (xx)
CY (1) CY1108408T1 (xx)
DE (1) DE602004015724D1 (xx)
DK (1) DK1585749T3 (xx)
EA (1) EA009337B1 (xx)
EC (1) ECSP055911A (xx)
ES (1) ES2309484T3 (xx)
GE (1) GEP20084367B (xx)
HK (1) HK1086257A1 (xx)
HR (1) HRP20050624A2 (xx)
IL (1) IL169082A (xx)
IS (1) IS7884A (xx)
MA (1) MA27703A1 (xx)
MX (1) MXPA05007352A (xx)
NO (1) NO20053775L (xx)
NZ (1) NZ540638A (xx)
OA (1) OA13017A (xx)
PL (1) PL378372A1 (xx)
PT (1) PT1585749E (xx)
RS (1) RS20050522A (xx)
SI (1) SI1585749T1 (xx)
TN (1) TNSN05176A1 (xx)
UA (1) UA80733C2 (xx)
WO (1) WO2004063198A1 (xx)
ZA (1) ZA200504674B (xx)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1467730A4 (en) * 2002-01-22 2010-03-10 Univ California Non-steroid ligands for the glucocorticoid receptor, compositions and uses thereof
CN1759118B (zh) * 2003-01-09 2010-12-08 美国辉瑞有限公司 作为激酶抑制剂的二氮杂*并吲哚衍生物
KR20070107034A (ko) * 2005-02-18 2007-11-06 아스트라제네카 아베 Ｃｈｋ1 억제제에 대한 반응성의 결정 방법
PT1869020E (pt) 2005-03-29 2010-12-23 Icos Corp Derivados de heteroaril-ureia úteis para a inibição de chk1
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
SI1896040T1 (sl) 2005-06-29 2012-12-31 Threshold Pharmaceuticals, Inc. Fosforamidatna alkilatorska predzdravila
CA2619048A1 (en) 2005-08-15 2007-02-22 The Regents Of The University Of California Vegf-activated fas ligands
CN101248184B (zh) 2005-08-25 2013-01-16 宇部兴产株式会社 光学活性（S或R）-α-氨基酸及光学活性（S或R）-α-氨基酸酯的制造方法
JP2009506077A (ja) * 2005-08-26 2009-02-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 非ステロイド性抗アンドロゲン剤
EP2004655A1 (en) * 2006-04-04 2008-12-24 Pfizer Products Incorporated Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4 l)-1-oxo-2,6-dihydro-1h-ý1,2¨diazepinoý4,5,6-cd¨indol-8-yl)acetamide
WO2007113671A1 (en) * 2006-04-04 2007-10-11 Pfizer Products Inc. Combination therapy of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
CA2669982A1 (en) * 2006-11-17 2008-05-29 Schering Corporation Combination therapy for proliferative disorders
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
JP5576370B2 (ja) * 2008-08-06 2014-08-20 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
WO2010040527A1 (en) * 2008-10-10 2010-04-15 Priaxon Ag Novel compounds which modulate kinase activity
US8314108B2 (en) 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (zh) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
CA2835195A1 (en) 2011-05-06 2012-11-15 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
WO2013096687A1 (en) * 2011-12-22 2013-06-27 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer
MX353578B (es) * 2011-12-31 2018-01-19 Beigene Ltd Dihidrodiazpinocarbazolonas tetra o penta-ciclicas fusionadas como inhibidores de poli (adp-ribosa) polimerasa (parp).
JP5913631B2 (ja) 2011-12-31 2016-05-11 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ピリドフタラジノン
CN102746211B (zh) * 2012-06-27 2015-05-27 上海泰坦化学有限公司 一种取代吲哚-3-甲醛类化合物的制备方法
TWI633107B (zh) * 2013-05-22 2018-08-21 開曼群島商百濟神州生物科技有限公司 作為ｐａｒｐ抑制劑的稠合四或五環二氫二氮呯并咔唑酮
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
WO2015069489A1 (en) 2013-11-06 2015-05-14 Merck Patent Gmbh Predictive biomarker for hypoxia-activated prodrug therapy
RS59054B1 (sr) 2014-06-17 2019-08-30 Vertex Pharma Postupak za lečenje raka korišćenjem kombinacije chk1 i atr inhibitora
CN107922425B (zh) * 2015-08-25 2021-06-01 百济神州有限公司 制备parp抑制剂、结晶形式的方法及其用途
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
US11202782B2 (en) 2016-09-27 2021-12-21 Beigene, Ltd. Treatment cancers using a combination comprising PARP inhibitors
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
WO2018157794A1 (en) 2017-02-28 2018-09-07 Beigene, Ltd. Crystalline forms of salts of fused tera or penta-cyclic dihydrodiazepinocarazolones, and uses thereof
US11661581B2 (en) * 2017-05-25 2023-05-30 University Of Massachusetts Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
SG11202002032SA (en) * 2017-09-22 2020-04-29 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN113631179A (zh) * 2019-01-25 2021-11-09 努梅迪公司 用于治疗特发性肺纤维化的方法
CN114072410B (zh) * 2019-08-01 2023-08-01 正大天晴药业集团股份有限公司 作为parp抑制剂吲哚并七元酰肟化合物
WO2021104461A1 (zh) 2019-11-29 2021-06-03 南京明德新药研发有限公司 二氮杂吲哚类衍生物及其作为Chk1抑制剂的应用
US20230330244A1 (en) * 2020-07-13 2023-10-19 Ontario Institute For Cancer Research (Oicr) Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereof
TW202214649A (zh) * 2020-07-31 2022-04-16 大陸商正大天晴藥業集團股份有限公司 用作ｐａｒｐ抑制劑的吲哚并七員醯肟類似物的結晶及其製備方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722320D0 (en) 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
US6383744B1 (en) 1998-07-10 2002-05-07 Incyte Genomics, Inc. Human checkpoint kinase
JP2002526450A (ja) 1998-09-18 2002-08-20 スミスクライン・ビーチャム・コーポレイション Ｃｈｋ１キナーゼ阻害物質
PL210415B1 (pl) * 1999-01-11 2012-01-31 Agouron Pharma Pochodne indolu, środek farmaceutyczny i zastosowanie pochodnych indolu
ATE388226T1 (de) 1999-08-27 2008-03-15 Novartis Vaccines & Diagnostic Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6670167B1 (en) 1999-11-01 2003-12-30 Agouron Pharmaceuticals, Inc. Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
WO2001021771A2 (en) 1999-09-22 2001-03-29 Canbas Co., Ltd. Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
ATE478664T1 (de) * 2000-12-01 2010-09-15 Eisai Inc Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
CN1759118B (zh) * 2003-01-09 2010-12-08 美国辉瑞有限公司 作为激酶抑制剂的二氮杂*并吲哚衍生物

Also Published As

Publication number Publication date
DK1585749T3 (da) 2008-09-22
CN1759118A (zh) 2006-04-12
US20070135415A1 (en) 2007-06-14
MXPA05007352A (es) 2006-02-17
CA2512683C (en) 2010-03-16
UA80733C2 (en) 2007-10-25
EP1585749A1 (en) 2005-10-19
EP1947102A1 (en) 2008-07-23
AU2004203977B2 (en) 2010-06-17
BRPI0406701A (pt) 2005-12-20
AP2048A (en) 2009-09-24
NO20053775D0 (no) 2005-08-08
CA2512683A1 (en) 2004-07-29
CY1108408T1 (el) 2014-02-12
IL169082A (en) 2011-02-28
HK1086257A1 (en) 2006-09-15
PT1585749E (pt) 2008-10-23
US20050075499A1 (en) 2005-04-07
WO2004063198A1 (en) 2004-07-29
JP2006516274A (ja) 2006-06-29
MA27703A1 (fr) 2006-01-02
US7462713B2 (en) 2008-12-09
ECSP055911A (es) 2005-11-22
RS20050522A (xx) 2007-12-31
NO20053775L (no) 2005-09-16
EA009337B1 (ru) 2007-12-28
US6967198B2 (en) 2005-11-22
JP3990718B2 (ja) 2007-10-17
AP2005003353A0 (en) 2005-09-30
EP1585749B1 (en) 2008-08-13
GEP20084367B (en) 2008-05-13
ES2309484T3 (es) 2008-12-16
PL378372A1 (pl) 2006-04-03
DE602004015724D1 (de) 2008-09-25
US7132533B2 (en) 2006-11-07
CN1759118B (zh) 2010-12-08
US20060004052A1 (en) 2006-01-05
HRP20050624A2 (en) 2006-02-28
EA200500893A1 (ru) 2006-02-24
SI1585749T1 (sl) 2008-10-31
NZ540638A (en) 2007-12-21
KR100697746B1 (ko) 2007-03-22
TNSN05176A1 (fr) 2007-06-11
ZA200504674B (en) 2006-07-26
IS7884A (is) 2005-06-09
ATE404564T1 (de) 2008-08-15
AU2004203977A1 (en) 2004-07-29
CR7899A (es) 2005-08-05
KR20050092397A (ko) 2005-09-21

Similar Documents

Publication Publication Date Title
OA13017A (en) Diazepinoindole derivatives as kinase inhibitors.
RU2730552C2 (ru) Спироконденсированные пирролидиновые производные в качестве ингибиторов деубиквитилирующих ферментов (DUB)
CN113286794B (zh) Kras突变蛋白抑制剂
JP2022541483A (ja) Ｐａｒｐ１阻害薬
EP2321316B1 (en) Substituted pyrimidin-4-one derivatives
WO2017158388A1 (en) 2-cyanoisoindoline derivatives for treating cancer
EA039783B1 (ru) ПРОИЗВОДНЫЕ ТИРОЗИНАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
JP5581220B2 (ja) 置換ヘテロアリールアミドオキサゼピノピリミドン誘導体
US9221826B2 (en) Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
TW200936588A (en) Substituted heteroarylamide diazepinopyrimidone derivatives
CA3117319A1 (en) Fused bicyclic heterocycles as thereapeutic agents
CN112654354A (zh) 1,3,4,9-四氢-2H-吡啶并[3,4-b]吲哚衍生物化合物及其用途
ES2969088T3 (es) Derivados de 1,4-dihidrobenzo[d]pirazolo[3,4-f][1,3]diazepina y compuestos relacionados como moduladores de quinasa LRRK2, NUAK1 y/o TYK2 para el tratamiento de e.g. enfermedades autoinmunes
CN115667218A (zh) 激酶抑制剂
CN114401954A (zh) 用于治疗自身免疫性疾病的哌啶基胺化合物
TW202023548A (zh) 新穎噻唑衍生物以及其藥用可接受鹽類